Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lukas

Showing results (11-20 of 90) with videos related to

Pageof 9
Sort By:
Current Pharmaceutical Design|March 15, 2006
The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapyRosario Calvo, John C Lukas, Monica Rodriguez, et al.
Seminars in Neurology|April 27, 2016
Optical Coherence Tomography in Multiple SclerosisJames V M Hanson, Sebastian C Lukas, Misha Pless, et al.
Pharmaceutical Research|October 4, 2017
Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study DesignValvanera Vozmediano, Ander Sologuren, John C Lukas, et al.
Biopharmaceutics & Drug Disposition|February 16, 2010
Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatmentJohn C Lukas, Rosario Calvo, Anastasios Zografidis, et al.
Immunotherapy|April 21, 2020
Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanomaT Gambichler, C Seifert, M Lehmann, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|September 20, 2012
Extensive cortical involvement in leptomeningeal carcinomatosisI Ayzenberg, C Börnke, C Tönnes, et al.
Oncogene|August 6, 1999
p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesisJ Lukas, C S Sørensen, C Lukas, et al.
Oncogene|September 26, 2001
Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathwayJ Falck, C Lukas, M Protopopova, et al.
Pharmaceutical Research|December 14, 2004
Pharmacokinetics of teicoplanin in an ICU population of children and infantsJohn C Lukas, Georgios Karikas, Maria Gazouli, et al.
Annals of the Rheumatic Diseases|July 24, 2007
Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritisE M Dias, C Lukas, R Landewé, et al.
Pageof 9

Showing results (11-20 of 90) with videos related to

Sort By:
Pageof 9
Current Pharmaceutical Design|March 15, 2006
The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapyRosario Calvo, John C Lukas, Monica Rodriguez, et al.
Seminars in Neurology|April 27, 2016
Optical Coherence Tomography in Multiple SclerosisJames V M Hanson, Sebastian C Lukas, Misha Pless, et al.
Pharmaceutical Research|October 4, 2017
Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study DesignValvanera Vozmediano, Ander Sologuren, John C Lukas, et al.
Biopharmaceutics & Drug Disposition|February 16, 2010
Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatmentJohn C Lukas, Rosario Calvo, Anastasios Zografidis, et al.
Immunotherapy|April 21, 2020
Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanomaT Gambichler, C Seifert, M Lehmann, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|September 20, 2012
Extensive cortical involvement in leptomeningeal carcinomatosisI Ayzenberg, C Börnke, C Tönnes, et al.
Oncogene|August 6, 1999
p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesisJ Lukas, C S Sørensen, C Lukas, et al.
Oncogene|September 26, 2001
Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathwayJ Falck, C Lukas, M Protopopova, et al.
Pharmaceutical Research|December 14, 2004
Pharmacokinetics of teicoplanin in an ICU population of children and infantsJohn C Lukas, Georgios Karikas, Maria Gazouli, et al.
Annals of the Rheumatic Diseases|July 24, 2007
Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritisE M Dias, C Lukas, R Landewé, et al.
Pageof 9